Emyria has been invited to join a group of emerging companies participating in Palantir Technologies’ foundry builders program, giving it access to data firm’s integration and analysis software.
Co-founded by PayPal’s Peter Thiel, Palantir Technologies provides data platforms for organisations with complex and sensitive environments including the US Food and Drug Administration (FDA), the National Institutes of Health and Sanofi.
The Palantir foundry builders program was established to allow select companies access to powerful and highly secure data integration and analysis software typically only available to major enterprises.
Under the program, Emyria will have access to the full Palantir foundry stack, enhancing its data infrastructure, security, integration, and analysis capabilities.
Palantir foundry will form the backbone of Emyria’s proprietary real-world evidence asset, as well as accelerating the company’s data-guided drug-development programs targeting FDA and Therapeutic Goods Administration registrations.
Managing director Dr Michael Winlo said: “We’re delighted to be selected to be part of the global Palantir ecosystem and leveraging one of the world’s most sophisticated and powered data platforms for our proprietary real-world evidence.
“Real-world evidence (RWE) is being increasingly used by major global drug regulators to evaluate the safety and efficacy of new treatments.
“Palantir foundry greatly improves our ability to secure, integrate, generate and analyse our RWE — both internally and with our global partners — meaning we can deliver on our mission to develop new treatments and improve patient care, faster.”
Emyria’s RWE asset now covers detailed and longitudinal health outcome data for more than 5,000 patients with complex medical conditions receiving unregistered treatments.